LOW INCIDENCE OF MDR1 EXPRESSION IN ACUTE PROMYELOCYTIC LEUKEMIA

被引：26

作者：

DRACH, D ^{[1
]}

ZHAO, SR ^{[1
]}

DRACH, J ^{[1
]}

ANDREEFF, M ^{[1
]}

机构：

[1] UNIV TEXAS,MD ANDERSON CANCER CTR,EXPTL HEMATOL SECT,HOUSTON,TX 77030

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 1995年 / 90卷 / 02期

关键词：

ACUTE PROMYELOCYTIC LEUKEMIA; MULTIDRUG RESISTANCE; P-GLYCOPROTEIN; CD34; ACUTE MYELOGENOUS LEUKEMIA;

D O I：

10.1111/j.1365-2141.1995.tb05161.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The MDR1. gene product, P-glycoprotein, functions as a transmembrane efflux pump for certain cytotoxic agents including anthracyclines, Based upon the clinical observation that patients with acute promyelocytic leukaemia (APL) respond favourably to anthracyclines, we hypothesized that APL cells may have low levels of MDR1 expression, We therefore investigated MDR1 expression in 10 patients with APL and compared results with those obtained in 18 patients with other subtypes of acute myelogenous leukaemia (AML). Prior to reverse transcriptase polymerase chain reaction with MDR1 specific primers, leukaemic cells were purified by fluorescence activated cell sorting to exclude normal haemopoietic cells, in particular lymphocytes, from the MDR1 analysis, In sorted APL cells, MDR1 expression was detected in only two of 10 patients, which was significantly different from findings in other AML subtypes (MDR1 expression in 14/18 patients; P < 0.01). When unsorted specimens from APL patients were studied, five of six cases were MDR1 positive, whereas sorted APL cells were shown to express MDR1 mRNA in only one of these cases. MDR1 mRNA levels expressed as MDR1/beta-2 microglobulin ratios were significantly lower in APL (0.24 +/- 0.2, mean +/- SD) than in AML (0.75 +/- 0.48; P < 0.01). We conclude that low or absent expression of MDR1 in APL cells may contribute to the efficacy of anthracyclines in the treatment of APL.

引用

页码：369 / 374

页数：6

共 39 条

[31]

Sato H., Preisler H., Day R., Raza A., Larson R., Browman G., Goldberg J., Vogler R., Grunwald H., Gottlieb A., Bennett J., Gottesman M., Pastan I., MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia, British Journal of Haematology, 75, pp. 340-345, (1990)

[32]

Scott S.C., Patel D., Drexler H.G., Master P.S., Limbert H.J., Roberts B.E., Immunophenotypic and enzymatic studies do not support the concept of mixed monocytic‐granulocytic differentiation in acute promyelocyte leukaemia (M3): a study of 44 cases, British Journal of Haematology, 71, pp. 505-509, (1989)

[33]

Sonneveld P., van Dongen J.M., Hagemeijer A., van Lorn K., Nooter K., Schoester M., Adriaansen H.J., Tsuruo T., de Leeuw K., High expression of the multidrug resistance P‐glycoprotein in high‐risk myelodysplasia is associated with immature phenotype, Leukemia, 7, pp. 963-969, (1993)

[34]

Stone R.M., Maguire M., Goldberg M.A., Antin J.H., Rosenthal D.S., Mayer R.J., Complete remission in acute promyelocytic leukemia despite persistence of abnormal bone marrow promyelocytes during induction therapy: experience in 34 patients, Blood, 71, pp. 690-696, (1988)

[35]

Stone R.M., Mayer R.J., The unique aspects of acute promyelocytic leukemia, Journal of Clinical Oncology, 8, pp. 1913-1921, (1990)

[36]

te Boekhorst P.A.W., de Leeuw K., Schoester M., Wittebol S., Nooter K., Hagemeijer A., Lowenberg B., Sonneveld P., Predominance of functional multidrug resistance (MDR‐1) phenotype in CD34<sup>+</sup> acute myeloid leukemia cells, Blood, 82, pp. 3157-3162, (1993)

[37]

Warrell R.P., Frankel S.R., Miller W.H., Scheinberg D.A., Itri L.M., Hittelman W.N., Vyas R., Andreeff M., Tafuri A., Jakubowski A., Gabrilove J., Gordon M.S., Dmitrovsky E., Differentiation therapy of acute promyelocytic leukemia with tretinoin (all‐trans‐retinoic acid), New England Journal of Medicine, 324, pp. 1385-1392, (1991)

[38]

Willman C.L., Kopecky K.J., Weick J., Appelbaum F., Grever M.R., Head D.R., Elias L., Balcerzak S.P., Mills G.M., Hynes H.M., Biologic parameters that predict treatment response in de novo acute myeloid leukemia (AML): CD34, but not multidrug resistance (MDR) gene expression is associated with a decreased complete remission (C/R) rate and CD34<sup>+</sup> patients more frequently achieve C/R rate with high dose cytosine arabinoside, Proceedings of ASCO, 11, (1992)

[39]

Zhou D.-C, Marie J.-P., Suberville A.-M., Zittoun R., Relevance of mdr‐1 gene expression in acute myeloid leukemia and comparison of different diagnostic methods, Leukemia, 6, pp. 879-885, (1992)

← 1 2 3 4 →